• News
  • SAN DIEGO
  • BioTech

DexCom cited as bellwether

CNBC stock commentator Jim Cramer on Friday cited San Diego’s DexCom Inc. (Nasdaq: DXCM) as a bellwether for the stock market, which should go into a turnaround on Wall Street within the next year.

In an interview with TheStreet, Cramer said DexCom had a “disruptive” diabetes monitoring system that has been grabbing an increasingly large part of the market. But he said the stock price has plummeted recently because investors have been focusing more on earnings per share instead of cash flow.

Cramer said the main reason DexCom’s earnings have weakened is that it has been adding more salespeople, which will help generate more revenues. He said if the stock starts bouncing back, it could bode well for similar stocks, signaling that investors are once again focusing on companies’ broader fundamentals.

DexCom shares, which briefly crested above $49 in early March, were selling at $32.45 at noon on Wall Street on Friday, after gaining a boost from Cramer's comments.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Dexcom Inc.

Company Website

5555 Oberlin Dr.
San Diego, CA 92121

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
DXCM
83.28
  -1.07  
- 1.27%
2,134,944,000
103.29
40.39

Insider Trade Data

Date Insider Shares Type Value
10/20/2015 Balo, Andrew K 4,538 Sell $369,670
10/19/2015 Roper, Jess 7,000 Sell $583,573
10/19/2015 Roper, Jess 6,000 Exchange $58,800
10/15/2015 Gregg, Terrance H 15,000 Sell $1,168,796
10/08/2015 Lister, John 2,750 Sell $211,748

Dexcom Inc. Executive(s):

Terrance Gregg

  • Chief Executive Officer, Director

Kevin Sayer

  • Director, President

Patrick Murphy

  • Assist. General Counsel
Subscribe Today!